不同部位胃腺癌第12a组淋巴结转移的危险因素分析

杜书祥, 赵英志, 张雪涛, 王涛, 骆晶钰, 张伟, 吴刚

  1. 1.河南省人民医院胃肠外科,河南 郑州 450003
    2.哈尔滨医科大学基础医学院,黑龙江 哈尔滨 150081
  • 收稿日期:2022-08-10 修回日期:2023-03-14 出版日期:2023-06-30 发布日期:2023-07-26
  • 通信作者: 吴刚
  • 作者简介:杜书祥(ROCID:0000-0002-2364-2028),硕士研究生在读。
  • 基金资助:
    河南省科技攻关项目(SBGJ202102028)

摘要/Abstract

摘要:

背景与目的:胃癌中肝十二指肠韧带内(沿肝动脉)淋巴结(第12a组淋巴结)转移规律尚不明确,其清扫指征仍有争议,目前缺乏大样本的相关临床研究数据。本研究通过观察不同部位胃癌第12a组淋巴结的转移率,探讨不同部位胃癌第12a组淋巴结转移的危险因素。方法:对河南省人民医院2016年5月—2021年7月胃外科收治的1 112例胃癌患者的病历资料进行回顾性分析,根据肿瘤位置分为胃上部癌(561例)、胃体癌(224例)、胃窦癌(327例),记录不同部位胃癌患者第12a组淋巴结转移率。采用χ2检验或Fisher确切概率检验比较不同部位胃癌患者第12a组淋巴结转移与临床病理学特征的关系,通过多因素logistic回归分析不同部位胃癌患者第12a组淋巴结转移的危险因素。结果:1 112例胃癌患者中72例发生第12a组淋巴结转移,整体转移率为6.5%。561例胃上部癌中有25例发生第12a组淋巴结转移,转移率为4.5%。224例胃体癌中有17例第12a组淋巴结为阳性,转移率为7.6%;327例胃窦癌中有30例第12a组淋巴结为阳性,转移率为9.2%。以第12a组淋巴结是否转移为因变量,以单因素分析差异有统计学意义的指标为自变量,纳入模型进行多因素logistic回归分析。结果显示,肿瘤直径(OR = 3.122,95% CI:2.896 ~ 3.366,P<0.001)、T分期(OR = 2.406,95% CI:1.705 ~ 3.396,P<0.001)及TNM分期(OR = 7.91,95% CI:4.755 ~ 13.160,P<0.001)是胃上部癌患者第12a组淋巴结转移的危险因素;肿瘤直径(OR = 2.757,95% CI:2.495 ~ 3.047,P<0.001)、T分期(OR = 3.298,95% CI:2.346 ~ 4.638,P <0.001)及脉管神经侵犯(OR = 1.839,95% CI:1.368 ~ 2.473,P<0.001)是胃体癌患者第12a组淋巴结转移的危险因素;体重指数(body mass index,BMI)(OR = 1.098,95% CI:1.023 ~ 1.178,P = 0.010)、肿瘤直径(OR = 2.865,95% CI:1.778 ~ 4.616,P<0.001)、T分期(OR = 13.497,95% CI:8.363 ~ 21.783,P<0.001)及TNM分期(OR = 3.806,95% CI:3.113 ~ 4.653,P <0.001)是胃窦癌患者第12a组淋巴结转移的危险因素。结论:第12a组淋巴结总转移率较低;肿瘤大小、浸润深度、肿瘤分期是胃癌第12a组淋巴结转移的独立危险因素,同时神经血管侵犯是胃体癌的独立危险因素;胃体、胃窦癌需要常规清扫第12a组淋巴结;胃上部癌第12a组淋巴结转移率低,不需要常规清扫,但当直径≥6 cm、肿瘤浸润深度较深(T3 ~ T4)、肿瘤分期较晚(Ⅲ ~ Ⅳ)时则需要清扫第12a组淋巴结。

关键词: 胃癌, 淋巴结转移率, 第12a组淋巴结

Abstract:

Background and purpose: It is not clear that the pattern of lymph node (group 12a) metastasis within the hepatoduodenal ligament (along the hepatic artery) in gastric cancer, its indications for dissection are still controversial, and there is a lack of relevant clinical study data from large samples. This study investigated the risk factors of lymph node group 12a metastasis in gastric cancer at different sites by observing the lymph node metastasis rate. Methods: The medical records of 1 112 gastric cancer patients admitted to the Department of Gastric Surgery in Henan Provincial People’s Hospital from May 2016 to July 2021 were retrospectively analyzed. According to tumor location, they were divided into upper gastric cancer (561 cases), gastric body cancer (224 cases) and gastric antrum cancer (327 cases). The lymph node metastasis rate of group 12a in patients with different parts of gastric cancer was recorded. The c2 test and Fisher’s exact probability test were used to compare the relationship between group 12a lymph node metastasis and clinicopathological features in patients with gastric cancer at different sites. Multivariate logistic regression analysis was used to analyze the risk factors of group 12a lymph node metastasis in patients with gastric cancer at different locations. Results: Group 12a lymph node metastasis occurred in 72 of 1 112 gastric cancer patients, and the overall metastatic rate was 6.5%. Among the 561 cases of upper gastric cancer, 25 cases developed group 12a lymph node metastasis, and the metastatic rate was 4.5%. Of the 224 patients with gastric body cancer, 17 cases were positive in group 12a lymph nodes, and the metastasis rate was 7.6%. Among the 327 cases of gastric antrum cancer, 30 cases were positive in group 12a lymph nodes, and the metastatic rate was 9.2%. Taking the lymph node metastasis in group 12a as the dependent variable, and taking the indicators with statistical significance in univariate analysis as independent variables, they were included in the model for multivariate logistic regression analysis. The results showed that tumor diameter (OR=3.122, 95% CI: 2.896-3.366, P<0.001), T stage (OR=2.406, 95% CI: 1.705-3.396, P<0.001), TNM stage (OR=7.910, 95% CI: 4.755-13.160, P<0.001) were risk factors for lymph node metastasis in group 12a of upper gastric cancer patients. Tumor diameter (OR=2.757, 95% CI: 2.495-3.047, P<0.001), T stage (OR=3.298, 95% CI: 2.346-4.638, P<0.001), vascular nerve invasion (OR=1.839, 95% CI: 1.368-2.473, P<0.001) were risk factors for lymph node metastasis in group 12a of patients with gastric body cancer. Body mass index (BMI) (OR=1.098, 95% CI: 1.023-1.178, P=0.010), tumor diameter (OR=2.865, 95% CI: 1.778-4.616, P<0.001), T stage (OR=13.497, 95% CI: 8.363-21.783, P<0.001), TNM stage (OR=3.806, 95% CI: 3.113-4.653, P<0.001) were risk factors for lymph node metastasis in group 12a of patients with gastric antrum cancer. Conclusion: The total lymph node metastasis rate in group 12a is low. Tumor size, invasion depth, N stage and tumor stage are independent risk factors for group 12a lymph node metastasis in gastric cancer. Besides, vascular nerve invasion is the independent risk factors for gastric body cancer. Gastric body cancer and gastric antrum cancer require routine dissection of group 12a lymph nodes. The metastatic rate of lymph nodes in group 12a of upper gastric cancer is low, and routine dissection is not required. However, when the diameter is ≥6 cm, the depth of tumor invasion is deep (T3-T4), and the tumor stage is late (Ⅲ-Ⅳ), group 12a lymph nodes need to be dissected.

Key words: Gastric cancer, Lymph node metastasis rate, Group 12a lymph nodes

中图分类号: 

相关文章

[1] 邹婷, 刘晓文. 胃癌同时性肝转移肝切除的疗效及预后分析[J]. 中国癌症杂志, 2023, 33(6): 605-612.
[2] 蒋金玲, 周尘飞, 王超, 赵丽琴, 吴珺玮, 张俊. 2022年度胃癌研究和诊疗新进展[J]. 中国癌症杂志, 2023, 33(4): 303-314.
[3] 肖岚姝, 潘柳荻, 刘毅, 王洁, 陈惠. LncRNA DLEU7-AS1通过调控膜突蛋白MSN的表达促进胃癌细胞增殖与迁移的作用机制[J]. 中国癌症杂志, 2023, 33(4): 327-341.
[4] 彭进, 王伟宁, 谭智, 叶冠男, 周震. m6Am修饰酶PCIF1调控靶基因ACOT8参与胃癌进展的机制研究[J]. 中国癌症杂志, 2023, 33(4): 368-376.
[5] 刘洋, 胡奕炀, 刘月平, 牛淑瑶, 丁平安, 田园, 郭洪海, 杨沛刚, 张泽, 郑涛, 檀碧波, 范立侨, 李勇, 赵群. 人工智能辅助技术在胃癌新辅助化疗患者HER2表达评估中的价值[J]. 中国癌症杂志, 2023, 33(4): 377-387.
[6] 陈馨宁, 姜惠琴, 杨轶慧, 虞倩, 张春燕, 王蓓丽, 潘柏申, 郭玮. 血浆Septin9基因甲基化状态和水平在胃癌患者诊断和预后评估中的应用价值[J]. 中国癌症杂志, 2023, 33(2): 162-167.
[7] 蔡钢, 王舒蓓, 陈佳艺. 放射治疗在胃癌全程管理中的现状与挑战[J]. 中国癌症杂志, 2022, 32(7): 581-587.
[8] 曹孟轩, 胡灿, 张延强, 黄灵, 杜义安, 于鹏程, 章若岚, 徐志远, 程向东. 胃癌根治术后早期复发转移的危险因素分析[J]. 中国癌症杂志, 2022, 32(7): 588-595.
[9] 蒋金玲, 周尘飞, 奚文崎, 施敏, 耿梅, 赵丽琴, 蔡劬, 蒋劲松, 张俊. 5-FU节拍化疗策略优化及调节胃癌免疫微环境的体内实验研究[J]. 中国癌症杂志, 2022, 32(7): 596-605.
[10] 张家祥, 周永学, 闫曙光, 赵唯含, 董汾. 缺氧诱导的线粒体自噬与糖代谢重编程对胃癌前病变影响的研究进展[J]. 中国癌症杂志, 2022, 32(10): 1007-1015.
[11] 张学成, 关晓辉 . Circ_0007142吸附miR-647调控CCR8基因促进胃癌细胞的上皮-间质转化和侵袭[J]. 中国癌症杂志, 2021, 31(8): 714-724.
[12] 龚 超, 陈 魁, 章德昆, 谢径峰, 吴芳华, 黄玉钿, 薛玉钦, 王力群 . 基于加权基因共表达网络分析构建胃癌转移预测模型[J]. 中国癌症杂志, 2021, 31(8): 746-753.
[13] 朱逸晖, 李 婷, 胡夕春. Trastuzumab deruxtecan的临床研究进展及展望——HER2耐药患者的新希望[J]. 中国癌症杂志, 2021, 31(8): 754-761.
[14] 郑培明, 李俊蒙, 张 鹏, 高 岚 . 巨噬细胞外泌体源miR-223促进胃癌细胞对奥沙利铂的耐药研究[J]. 中国癌症杂志, 2021, 31(5): 368-378.
[15] 刘 斌, 郑鹏远, 米 阳, 任飞飞, 高 爽, 刘 传, 李发展 . LRP8在胃癌中的表达及其在胃癌发生过程中的作用[J]. 中国癌症杂志, 2021, 31(4): 285-293.